Two-year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children (MOSAIC) clinical trial.

ABSTRACT:

Purpose

To investigate 2-year changes in macular choroidal thickness (ChT) in children receiving 0.01% atropine eyedrops and its relationship with spherical equivalent refraction (SER) progression and axial length (AL) elongation.

Methods

A total of 250 myopic children aged 6-16 years (167%-0.01% atropine, 83-placebo) were enrolled in the MOSAIC (ISRCTN36732601) clinical trial. Participants with complete 2-year ChT (Topcon Triton Swept-Source OCT), SER, and AL data were included in this study. Changes in macular ChT at 2 years and associations with changes in SER and AL elongation were analysed using linear mixed models.

Results

A total of 187 children (126%-0.01% atropine, 61-placebo) were included in the analysis. Choroidal thickness over 2 years was stable in the 0

SUBMITTER: Kobia-Acquah E 

PROVIDER: S-EPMC12604447 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature